The authors try to decide a problem of ovarian cancer resistance to platinum drugs by the way of correlation finding between platinum-resistance of tumor and presence of gene mutations in the patient.It was shown a va...The authors try to decide a problem of ovarian cancer resistance to platinum drugs by the way of correlation finding between platinum-resistance of tumor and presence of gene mutations in the patient.It was shown a variety of options for BRCA gene mutations in patients with ovarian cancer:BRCA 1(185delAG)-64.2%,BRCA 1(5382 insC)-55.7%,and BRCA 2(6174delT)-53.8%.Authors discovered a significant positive correlation between carriage of mutations in the BRCA genes 1/2 and the sensitivity of malignant ovarian tumors to chemotherapy with platinum.Mutations in these genes occurred significantly more often in patients with platinum-sensitive ovarian cancer.展开更多
BACKGROUND AND OBJECTIVES: The objective of this study was to assess the antitumor activity and toxicity profile of gemcitabine combined with epirubicin in patients with recurrent platinum refractory ovarian epithelia...BACKGROUND AND OBJECTIVES: The objective of this study was to assess the antitumor activity and toxicity profile of gemcitabine combined with epirubicin in patients with recurrent platinum refractory ovarian epithelial cancer. PATIENTS AND METHODS: Patients with recurrent platinum refractory ovarian cancer and with adequate hematologic, renal and hepatic function and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 were enrolled. The regimen was Gemcitabine 1000 mg/m2 (day 1, 8) and Epirubicin 60 mg/m2 (day 1), the cycle was repeated at interval of 21 days. RESULTS: Twenty eight patients were recruited and received 156 cycles of gemcitabine-epirubicin combination chemotherapy (median 6 cycles). Overall response rate was 42.9% (95% CI equal 24.5 to 62.7) and tumor control rate was 75% (95% CI equal 55.1 to 89.3). No complete responses were observed. Median progression-free and median overall survival times were 7 and 15 months, respectively. The most common grade 3/4 hematological toxicities were neutropenia (57.1%), anemia (10.7%), and thrombocytopenia (7.1%), while the most common grade 3/4 non-hematological toxicities were mucositis (14.3%) and vomiting (3.6%). No treatment related deaths were observed. CONCLUSION: Gemcitabine combined with epirubicin regimen appeared to offer an acceptable clinical profile in patients with recurrent platinum-refractory epithelial ovarian cancer.展开更多
Objective The aim of the study was to evaluate the role of ATP-based tumor chemosensitivity assay(ATP-TCA) in patients with platinum-resistant recurrent ovarian cancer(PRROC).Methods A total of 43 patients with PRROC ...Objective The aim of the study was to evaluate the role of ATP-based tumor chemosensitivity assay(ATP-TCA) in patients with platinum-resistant recurrent ovarian cancer(PRROC).Methods A total of 43 patients with PRROC who underwent chemotherapy based on the results of ATPTCA in the Cancer Hospital,Chinese Academy of Medical Sciences were included in the present study.As controls,we selected another 43 patients with PRROC who were treated at the physician's discretion within the same time period and had the same clinical characteristics as the patients in the ATP-TCA group.Logrank test and Cox proportional hazards model were adopted for analysis.Results A total of 86 patients were retrospectively analyzed in the present study.Patients were routinely monitored to evaluate the rate of progression-free survival(PFS).The median follow-up time was 13 months.The PFS for the ATP-TCA and control groups was 5 and 3 months,respectively(P = 0.027).Multivariate analysis showed that the type of treatment was an independent prognostic factor for PFS(P = 0.040;HR:0.623;95% CI:0.313–0.973).Subgroup analysis showed that among patients with a treatmentfree interval(TFI) of ≥ 3 months(n = 50),those in the ATP-TCA group had longer PFS than those in the control group(7 vs 4 months,P = 0.010).Meanwhile,the median PFS of patients who underwent ≤ 2 prior chemotherapy regimens(PCR,n = 52) in the ATP-TCA and control groups was 6 months and 4 months,respectively(P = 0.025).Conclusion ATP-TCA-directed chemotherapy might improve the PFS in PRROC.In particular,the survival benefit from ATP-TCA is higher in patients with a TFI of ≥ 3 months or treated with ≤ 2 PCR.展开更多
目的构建预测上皮性卵巢癌(epithelial ovarian cancer,EOC)铂耐药复发的风险模型。方法回顾性分析2012年1月1日至2022年6月30日在云南省肿瘤医院行手术治疗的1392例EOC患者的临床病理资料。对可能影响铂耐药复发的16个因素进行单因素...目的构建预测上皮性卵巢癌(epithelial ovarian cancer,EOC)铂耐药复发的风险模型。方法回顾性分析2012年1月1日至2022年6月30日在云南省肿瘤医院行手术治疗的1392例EOC患者的临床病理资料。对可能影响铂耐药复发的16个因素进行单因素和多因素logistic回归分析并构建logistic回归预测模型。采用加强Bootstrap法对模型进行内部验证。模型表现通过受试者工作特征(receiver operating characteristic,ROC)曲线下面积(area under the curve,AUC)、敏感度、特异度和Brier得分评价,并将模型可视化为列线图和网页计算器。结果多因素logistic回归分析显示,血清乳酸脱氢酶水平、国际妇产科联合会(International Federation of Gynecology and Obstetrics,FIGO)分期、术后化疗周期和血小板计数均是影响EOC铂耐药复发的独立影响因素(均P<0.05)。基于年龄和上述变量构建的logistic回归模型的AUC、敏感度和特异度分别为0.704、62.0%和68.4%。模型在内部验证中的Brier得分为0.002。结论基于乳酸脱氢酶开发的预测EOC患者铂耐药复发的列线图可用于指导临床实践。展开更多
文摘The authors try to decide a problem of ovarian cancer resistance to platinum drugs by the way of correlation finding between platinum-resistance of tumor and presence of gene mutations in the patient.It was shown a variety of options for BRCA gene mutations in patients with ovarian cancer:BRCA 1(185delAG)-64.2%,BRCA 1(5382 insC)-55.7%,and BRCA 2(6174delT)-53.8%.Authors discovered a significant positive correlation between carriage of mutations in the BRCA genes 1/2 and the sensitivity of malignant ovarian tumors to chemotherapy with platinum.Mutations in these genes occurred significantly more often in patients with platinum-sensitive ovarian cancer.
文摘BACKGROUND AND OBJECTIVES: The objective of this study was to assess the antitumor activity and toxicity profile of gemcitabine combined with epirubicin in patients with recurrent platinum refractory ovarian epithelial cancer. PATIENTS AND METHODS: Patients with recurrent platinum refractory ovarian cancer and with adequate hematologic, renal and hepatic function and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 were enrolled. The regimen was Gemcitabine 1000 mg/m2 (day 1, 8) and Epirubicin 60 mg/m2 (day 1), the cycle was repeated at interval of 21 days. RESULTS: Twenty eight patients were recruited and received 156 cycles of gemcitabine-epirubicin combination chemotherapy (median 6 cycles). Overall response rate was 42.9% (95% CI equal 24.5 to 62.7) and tumor control rate was 75% (95% CI equal 55.1 to 89.3). No complete responses were observed. Median progression-free and median overall survival times were 7 and 15 months, respectively. The most common grade 3/4 hematological toxicities were neutropenia (57.1%), anemia (10.7%), and thrombocytopenia (7.1%), while the most common grade 3/4 non-hematological toxicities were mucositis (14.3%) and vomiting (3.6%). No treatment related deaths were observed. CONCLUSION: Gemcitabine combined with epirubicin regimen appeared to offer an acceptable clinical profile in patients with recurrent platinum-refractory epithelial ovarian cancer.
基金Supported by a grant from the Capital’s Funds for Health Improvement and Research(No.Z131107002213013)
文摘Objective The aim of the study was to evaluate the role of ATP-based tumor chemosensitivity assay(ATP-TCA) in patients with platinum-resistant recurrent ovarian cancer(PRROC).Methods A total of 43 patients with PRROC who underwent chemotherapy based on the results of ATPTCA in the Cancer Hospital,Chinese Academy of Medical Sciences were included in the present study.As controls,we selected another 43 patients with PRROC who were treated at the physician's discretion within the same time period and had the same clinical characteristics as the patients in the ATP-TCA group.Logrank test and Cox proportional hazards model were adopted for analysis.Results A total of 86 patients were retrospectively analyzed in the present study.Patients were routinely monitored to evaluate the rate of progression-free survival(PFS).The median follow-up time was 13 months.The PFS for the ATP-TCA and control groups was 5 and 3 months,respectively(P = 0.027).Multivariate analysis showed that the type of treatment was an independent prognostic factor for PFS(P = 0.040;HR:0.623;95% CI:0.313–0.973).Subgroup analysis showed that among patients with a treatmentfree interval(TFI) of ≥ 3 months(n = 50),those in the ATP-TCA group had longer PFS than those in the control group(7 vs 4 months,P = 0.010).Meanwhile,the median PFS of patients who underwent ≤ 2 prior chemotherapy regimens(PCR,n = 52) in the ATP-TCA and control groups was 6 months and 4 months,respectively(P = 0.025).Conclusion ATP-TCA-directed chemotherapy might improve the PFS in PRROC.In particular,the survival benefit from ATP-TCA is higher in patients with a TFI of ≥ 3 months or treated with ≤ 2 PCR.
文摘目的构建预测上皮性卵巢癌(epithelial ovarian cancer,EOC)铂耐药复发的风险模型。方法回顾性分析2012年1月1日至2022年6月30日在云南省肿瘤医院行手术治疗的1392例EOC患者的临床病理资料。对可能影响铂耐药复发的16个因素进行单因素和多因素logistic回归分析并构建logistic回归预测模型。采用加强Bootstrap法对模型进行内部验证。模型表现通过受试者工作特征(receiver operating characteristic,ROC)曲线下面积(area under the curve,AUC)、敏感度、特异度和Brier得分评价,并将模型可视化为列线图和网页计算器。结果多因素logistic回归分析显示,血清乳酸脱氢酶水平、国际妇产科联合会(International Federation of Gynecology and Obstetrics,FIGO)分期、术后化疗周期和血小板计数均是影响EOC铂耐药复发的独立影响因素(均P<0.05)。基于年龄和上述变量构建的logistic回归模型的AUC、敏感度和特异度分别为0.704、62.0%和68.4%。模型在内部验证中的Brier得分为0.002。结论基于乳酸脱氢酶开发的预测EOC患者铂耐药复发的列线图可用于指导临床实践。
